X4 Pharmaceuticals, Inc (XFOR) shareholders
Close on Nov 17, 2026Market cap $306.36MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Anders Hove Joint filing with Acorn Bioventures 2 L.P. (6.50%), Acorn Capital Advisors GP 2, LLC (6.50%) | 17,755,869 | 9.99% | 13G (passive) | Dec 31, 2023 |
| Empery Asset Management, LP Joint filing with Ryan M. Lane (9.99%) | 9,043,894 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Morgan Stanley Joint filing with Morgan Stanley Investment Management Inc. (10.20%), Inception Trust (5.20%) | 8,884,338 | 10.20% | 13G (passive) amendment | Feb 28, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (8.10%), Joseph Edelman (8.10%) | 8,085,006 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (8.33%), Deep Track Biotechnology Master Fund, Ltd. (7.18%) | 8,040,894 | 8.33% | 13G (passive) amendment | Jun 30, 2026 |
| BCLS II Equity Opportunities, LP | 7,047,216 | 7.43% | 13G (passive) amendment | Dec 31, 2025 |
| Xiaoying Tian Joint filing with Saturn V Capital Management LP (7.36%) | 6,433,481 | 7.36% | 13G (passive) | Oct 24, 2025 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (7.60%), Perceptive Life Sciences Master Fund, Ltd. (7.60%) | 6,064,680 | 7.60% | 13G (passive) | Oct 27, 2025 |
| Venrock Healthcare Capital Partners III, L.P. Joint filing with VHCP Co-Investment Holdings III, LLC (5.60%), Venrock Healthcare Capital Partners EG, L.P. (5.60%) and 4 more | 5,555,047 | 5.60% | 13G (passive) | Sep 14, 2026 |
| BlackRock, Inc. | 5,529,573 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Trails Edge Capital Partners, LP Joint filing with Trails Edge Biotechnology Master Fund, LP (5.80%), Ortav Yehudai (5.80%) | 5,227,222 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
| NEA Partners 18 VGE, L.P. Joint filing with Growth Equity Opportunities 18 VGE, LLC (6.20%), NEA 18 Venture Growth Equity, L.P. (6.20%) and 9 more | 5,057,610 | 6.20% | 13D (active) amendment | Oct 27, 2025 |
| Hoe Martin D. Joint filing with Empery Asset Management, LP (9.99%), Lane Ryan M. (9.99%) | 2,498,162 | 9.99% | 13G (passive) | Sep 30, 2025 |
| Coastlands Capital GP LLC Joint filing with Coastlands Capital LP (9.99%), Coastlands Capital Partners LP (9.99%) and 2 more | 2,491,638 | 9.99% | 13G (passive) | Oct 3, 2025 |
| Coastlands Capital LLC Joint filing with Coastlands Capital LP (9.99%), Coastlands Capital Partners LP (9.99%) and 2 more | 2,479,645 | 9.99% | 13D (active) | Aug 11, 2025 |
| Bain Capital Life Sciences Fund II, L.P. Joint filing with Bain Capital Life Sciences Fund, L.P. (9.99%), BCIP Life Sciences Associates, LP (9.99%) and 3 more | 2,436,588 | 9.99% | 13G (passive) | Sep 9, 2025 |
| Bain Capital Life Sciences Fund, L.P. Joint filing with Bain Capital Life Sciences Fund II, L.P. (9.99%), BCIP Life Sciences Associates, LP (9.99%) and 2 more | 2,436,526 | 9.99% | 13D (active) | Aug 11, 2025 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (9.99%), David Kroin (9.99%) | 2,366,995 | 9.99% | 13G (passive) | Aug 12, 2025 |
| Trails Edge Biotechnology Master Fund, LP Joint filing with Trails Edge Capital Partners, LP (9.90%), Ortav Yehudai (9.90%) | 2,317,153 | 9.90% | 13G (passive) | Aug 11, 2025 |
| Rick Yang Joint filing with Growth Equity Opportunities 18 VGE, LLC (9.99%), NEA 18 Venture Growth Equity, L.P. (9.99%) and 9 more | 2,243,658 | 9.99% | 13D (active) amendment | Aug 13, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XFOR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 9,461,279 | 9.54% | $44.18M | −5,713 | 0.00% |
| FMR LLC | 8,321,657 | 8.39% | $38.86M | +218,257 | 0.00% |
| Bain Capital Life Sciences Investors, LLC | 7,967,454 | 8.04% | $37.21M | – | 2.21% |
| Perceptive Advisors LLC | 7,933,491 | 8.00% | $37.05M | +1,195,843 | 0.56% |
| Kalehua Capital Management LLC | 7,445,680 | 7.51% | $34.77M | – | 11.09% |
| Saturn V Capital Management LP | 6,973,343 | 7.03% | $32.57M | +516,697 | 4.67% |
| Empery Asset Management, LP | 6,930,591 | 6.99% | $32.37M | −2,013,527 | 37.43% |
| Deep Track Capital, LP | 5,878,757 | 5.93% | $27.45M | −460,778 | 0.40% |
| BlackRock, Inc. | 5,554,906 | 5.60% | $25.94M | +4,343,112 | 0.00% |
| Nantahala Capital Management, LLC | 4,898,936 | 4.94% | $22.88M | +2,449,468 | 0.38% |
| Vanguard Capital Management LLC | 3,715,859 | 3.75% | $17.35M | +218,247 | 0.00% |
| Rosalind Advisors, Inc. | 3,214,766 | 3.24% | $15.01M | – | 5.58% |
| Braidwell LP | 2,922,754 | 2.95% | $13.65M | −350,200 | 0.50% |
| Blackstone Inc. | 2,681,922 | 2.71% | $12.52M | – | 0.04% |
| Trails Edge Capital Partners, LP | 2,571,478 | 2.59% | $12.01M | – | 1.91% |
| Bvf Inc/Il | 2,233,742 | 2.25% | $10.43M | – | 0.27% |
| Geode Capital Management, LLC | 2,098,047 | 2.12% | $9.80M | +1,158,321 | 0.00% |
| VR Adviser, LLC | 1,934,253 | 1.95% | $9.03M | +1,603,728 | 0.27% |
| Samsara BioCapital, LLC | 1,395,587 | 1.41% | $6.52M | −436,979 | 0.54% |
| State Street Corp | 1,296,017 | 1.31% | $6.05M | +892,483 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 88 | 102M | 100.0% | 32 / 25 | 13 / 26 | 16M | 9M |
| Q1 2026 | 82 | 95M | 95.8% | 18 / 24 | 21 / 10 | 17M | 4M |
| Q4 2025 | 76 | 86M | 86.7% | 41 / 16 | 8 / 4 | 74M | 2M |
| Q3 2025 | 40 | 14M | 13.8% | 11 / 10 | 10 / 20 | 12M | 1M |
| Q2 2025 | 49 | 2M | 2.2% | 48 / 1 | 0 / 1 | 2M | 0M |
| Q1 2025 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
61 funds held XFOR in Q2 2026, 33% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of XFOR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 3,386,200 | 3.42% | $13.48M | 0.15% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,599,387 | 2.62% | $12.14M | 0.00% | Jun 30, 2026 |
| Inception Portfolio | 2,308,518 | 2.33% | $10.78M | 3.82% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,907,416 | 1.92% | $8.91M | 0.01% | Jun 30, 2026 |
| EQ/Morgan Stanley Small Cap Growth Portfolio | 1,817,124 | 1.83% | $8.49M | 1.79% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 1,689,700 | 1.70% | $6.73M | 0.15% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 1,428,500 | 1.44% | $6.16M | 0.12% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,341,800 | 1.35% | $5.34M | 0.24% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,032,028 | 1.04% | $4.82M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 884,763 | 0.89% | $3.52M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 758,220 | 0.76% | $3.54M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Stock Fund | 504,600 | 0.51% | $2.01M | 0.15% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 422,860 | 0.43% | $1.82M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 271,214 | 0.27% | $1.27M | 0.08% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 196,530 | 0.20% | $782.19K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adam R. Craig | Executive Chairman, Director | 333,251 | 0.34% | Oct 19, 2026 |
| Paula Ragan | President and CEO, Director | 3,337,386 | 3.37% | Feb 14, 2025 |
| David Kirske | Chief Financial Officer | 155,983 | 0.16% | Oct 5, 2026 |
| John Volpone | President | 265,305 | 0.27% | Aug 13, 2026 |
| Natasha Fay Thoren | Chief Legal Officer | 9,462 | 0.01% | Jul 3, 2025 |
| Mark Baldry | Chief Commercial Officer | 25,337 | 0.03% | Jun 3, 2025 |
| Mary DiBiase | Chief Operating Officer | 1,140,980 | 1.15% | Feb 14, 2025 |
| Adam S. Mostafa | Chief Financial Officer | 850,000 | 0.86% | Feb 14, 2025 |
| Christophe Arbet-Engels | Chief Medical Officer | 864,207 | 0.87% | Feb 14, 2025 |
| Kelly Gold | Director | – | – | Jul 1, 2026 |
| Gary Bridger | Director | 4,722 | 0.00% | Jan 7, 2026 |
| Murray Stewart | Director | 7,883 | 0.01% | Jan 5, 2026 |
| Michael S. Wyzga | Director | 5,555 | 0.01% | Jan 5, 2026 |
| Craecker Francoise de | Director | 4,722 | 0.00% | Jan 5, 2026 |
| David W. J. McGirr | Director | 4,722 | 0.00% | Jun 10, 2025 |
| Keith Woods | Director | 6,000 | 0.01% | Jun 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adam R. Craig Executive Chairman, Director | Oct 16, 2026 | Buy | +4,600 | $2.58 | $11.88K | 333,251 |
| David Kirske Chief Financial Officer | Oct 1, 2026 | Sale | −11,767 | $2.86 | $33.66K | 155,983 |
| John Volpone President | Aug 12, 2026 | Sale | −24,576 | $4.44 | $109.12K | 265,305 |
| Adam R. Craig Executive Chairman, Director | Aug 12, 2026 | Sale | −47,436 | $4.44 | $210.62K | 328,651 |
| David Kirske Chief Financial Officer | Jun 30, 2026 | Sale | −8,543 | $4.26 | $36.39K | 167,750 |
| David Kirske Chief Financial Officer | May 12, 2026 | Sale | −16,961 | $4.29 | $72.76K | 176,293 |
| Adam R. Craig Executive Chairman, Director | Oct 23, 2025 | Buy | +86,206 | $2.90 | $250.00K | 376,087 |
| Adam R. Craig Executive Chairman, Director | Aug 14, 2025 | Award | +289,881 | – | – | 289,881 |
| David Kirske Chief Financial Officer | Aug 14, 2025 | Award | +193,254 | – | – | 193,254 |
| John Volpone President | Aug 14, 2025 | Award | +289,881 | – | – | 289,881 |
| Murray Stewart Director | Jun 9, 2025 | Award | +1,500 | – | – | 7,883 |
| Craecker Francoise de Director | Jun 9, 2025 | Award | +1,500 | – | – | 4,722 |
| David W. J. McGirr Director | Jun 9, 2025 | Award | +1,500 | – | – | 4,722 |
| Michael S. Wyzga Director | Jun 9, 2025 | Award | +1,500 | – | – | 5,555 |
| Keith Woods Director | Jun 9, 2025 | Award | +1,500 | – | – | 6,000 |
| Gary Bridger Director | Jun 9, 2025 | Award | +1,500 | – | – | 4,722 |
| Natasha Fay Thoren Chief Legal Officer | May 20, 2025 | Award | +3,333 | – | – | 9,462 |
| Mark Baldry Chief Commercial Officer | May 16, 2025 | Award | +1,032 | $2.48 | $2.56K | 25,337 |
| Mark Baldry Chief Commercial Officer | May 16, 2025 | Buy | +1,032 | $2.48 | $2.56K | 25,337 |
| Adam S. Mostafa Chief Financial Officer | Feb 12, 2025 | Award | +850,000 | – | – | 850,000 |
| Mark Baldry Chief Commercial Officer | Feb 12, 2025 | Award | +600,000 | – | – | 729,173 |
| Christophe Arbet-Engels Chief Medical Officer | Feb 12, 2025 | Award | +850,000 | – | – | 864,207 |
| Mary DiBiase Chief Operating Officer | Feb 12, 2025 | Award | +650,000 | – | – | 1,140,980 |
| Paula Ragan President and CEO, Director | Feb 12, 2025 | Award | +2,250,000 | – | – | 3,337,386 |
| Mark Baldry Chief Commercial Officer | Jan 24, 2025 | Sale(10b5-1 plan) | −29,159 | $0.45 | $13.12K | 94,123 |
| Mary DiBiase Chief Operating Officer | Jan 24, 2025 | Sale(10b5-1 plan) | −22,258 | $0.45 | $10.02K | 490,980 |
| Paula Ragan President and CEO, Director | Jan 24, 2025 | Sale(10b5-1 plan) | −76,473 | $0.45 | $34.41K | 1,087,386 |
| Adam S. Mostafa Chief Financial Officer | Jan 24, 2025 | Sale(10b5-1 plan) | −74,773 | $0.45 | $33.65K | 0 |
| Christophe Arbet-Engels Chief Medical Officer | Jan 24, 2025 | Sale(10b5-1 plan) | −11,624 | $0.45 | $5.23K | 14,207 |
| Mark Baldry Chief Commercial Officer | Jan 23, 2025 | Award | +74,773 | – | – | 123,282 |
| Mary DiBiase Chief Operating Officer | Jan 23, 2025 | Award | +61,178 | – | – | 513,238 |
| Paula Ragan President and CEO, Director | Jan 23, 2025 | Award | +169,940 | – | – | 1,163,859 |
| Adam S. Mostafa Chief Financial Officer | Jan 23, 2025 | Award | +74,773 | – | – | 74,773 |
| Christophe Arbet-Engels Chief Medical Officer | Jan 23, 2025 | Award | +25,831 | – | – | 25,831 |
| Mark Baldry Chief Commercial Officer | Nov 15, 2024 | Buy | +13,404 | $0.34 | $4.56K | 129,173 |
| Paula Ragan President and CEO, Director | Nov 15, 2024 | Sale(10b5-1 plan) | −31,897 | $0.39 | $12.44K | 993,919 |
| Paula Ragan President and CEO, Director | Oct 15, 2024 | Sale(10b5-1 plan) | −31,897 | $0.56 | $17.86K | 1,025,816 |
| Adam S. Mostafa Chief Financial Officer | Oct 7, 2024 | Sale(10b5-1 plan) | −230,645 | $0.55 | $126.85K | 0 |
| Arthur Taveras Chief Scientific Officer | Oct 7, 2024 | Sale(10b5-1 plan) | −76,920 | $0.56 | $43.08K | 388,026 |
| Mary DiBiase Chief Operating Officer | Oct 7, 2024 | Sale(10b5-1 plan) | −67,695 | $0.57 | $38.59K | 452,060 |
| Mark Baldry Chief Commercial Officer | Oct 7, 2024 | Sale(10b5-1 plan) | −11,127 | $0.58 | $6.45K | 48,509 |
| Paula Ragan President and CEO, Director | Oct 7, 2024 | Sale(10b5-1 plan) | −239,436 | $0.55 | $131.69K | 1,057,713 |
| Adam S. Mostafa Chief Financial Officer | Oct 4, 2024 | Award | +230,645 | – | – | 230,645 |
| Arthur Taveras Chief Scientific Officer | Oct 4, 2024 | Award | +230,645 | – | – | 464,946 |
| Mary DiBiase Chief Operating Officer | Oct 4, 2024 | Award | +230,645 | – | – | 519,755 |
| Mark Baldry Chief Commercial Officer | Oct 4, 2024 | Award | +34,946 | – | – | 59,636 |
| Paula Ragan President and CEO, Director | Oct 4, 2024 | Award | +532,081 | – | – | 1,297,149 |
| Mary DiBiase Chief Operating Officer | Sep 9, 2024 | Sale | −2,642 | $0.66 | $1.74K | 289,110 |
| Craecker Francoise de Director | Jun 10, 2024 | Award | +45,000 | – | – | 96,667 |
| William Aliski Director | Jun 10, 2024 | Award | +45,000 | – | – | 96,667 |
| David W. J. McGirr Director | Jun 10, 2024 | Award | +45,000 | – | – | 96,667 |
| Keith Woods Director | Jun 10, 2024 | Award | +45,000 | – | – | 135,000 |
| Alison Frances Lawton Director | Jun 10, 2024 | Award | +45,000 | – | – | 96,667 |
| Gary Bridger Director | Jun 10, 2024 | Award | +45,000 | – | – | 96,667 |
| Murray Stewart Director | Jun 10, 2024 | Award | +45,000 | – | – | 191,504 |
| Michael S. Wyzga Director | Jun 10, 2024 | Award | +45,000 | – | – | 121,667 |
| Mark Baldry Chief Commercial Officer | May 17, 2024 | Buy | +21,646 | $0.68 | $14.72K | 115,769 |
| Arthur Taveras Chief Scientific Officer | Mar 11, 2024 | Sale | −14,235 | $0.88 | $12.53K | 234,301 |
| Paula Ragan President and CEO, Director | Mar 11, 2024 | Sale | −49,678 | $0.88 | $43.72K | 765,068 |
| Mary DiBiase Chief Operating Officer | Mar 11, 2024 | Sale | −15,409 | $0.88 | $13.56K | 291,752 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of X4 Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 298,075 shares on Sep 16, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Kirske Officer | Oct 1, 2026 | 11,767 | $33.66K | Oct 1, 2026 | Restricted Stock Unit Vesting |
| Adam R. Craig Executive Chaiman | Aug 13, 2026 | 47,436 | $216.07K | Aug 12, 2026 | Restricted Stock Unit Vesting |
| John Volpone Officer | Aug 13, 2026 | 24,576 | $111.94K | Aug 12, 2026 | Restricted Stock Unit Vesting |
| David Kirske Officer | May 12, 2026 | 16,961 | $72.82K | May 12, 2026 | Restricted Stock Unit Vesting |
| Paula Ragan Officer | Jan 24, 2025 | 76,473 | $39.77K | Jan 24, 2025 | PRSU Vesting |
| Arthur Taveras Officer | Jan 24, 2025 | 24,828 | $12.91K | Jan 24, 2025 | PRSU Vesting |
| Adam S. Mostafa Officer | Jan 24, 2025 | 74,773 | $38.88K | Oct 7, 2024 | PRSU |
| Mark Baldry Officer | Jan 24, 2025 | 29,159 | $15.16K | Jan 24, 2025 | Stock Award |
| Christophe Arbet-Engels Officer | Jan 24, 2025 | 11,624 | $6.04K | Jan 24, 2025 | Stock Award |
| Mary DiBiase Officer | Jan 24, 2025 | 22,258 | $11.57K | Jan 24, 2025 | PRSU Vesting |
| Paula Ragan Officer | Nov 15, 2024 | 31,897 | $13.08K | Nov 15, 2024 | RSU/PRSU Vest |
| Paula Ragan Officer | Oct 15, 2024 | 31,897 | $17.86K | Oct 15, 2024 | RSU/PRSU Vest |
| Mark Baldry Officer | Oct 7, 2024 | 11,127 | $7.08K | Oct 7, 2024 | Stock Award |
| Adam S. Mostafa Officer | Oct 7, 2024 | 230,645 | $146.83K | Oct 7, 2024 | PRSU |
| Paula Ragan Officer | Oct 7, 2024 | 239,436 | $152.42K | Oct 7, 2024 | Stock Award |
See a number that looks wrong?